De­bio­pharm, ITM ink €300M li­cens­ing deal for can­cer treat­ment

De­bio­pharm and ITM an­nounced a li­cens­ing deal for a ​​ra­dio­phar­ma­ceu­ti­cal treat­ment that’s be­ing in­ves­ti­gat­ed in sev­er­al can­cers.

De­bio­pharm, which is based in Switzer­land, is el­i­gi­ble …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER